The role of JAK-STAT signaling pathway in early arthritis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Tipo de documento: | Dissertação |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10362/162939 |
Resumo: | Rheumatoid arthritis (RA) is a systemic, inflammatory, immune-mediated disorder, impacting approximately 1% of the world population. It is characterized by chronic joint inflammation due to accumulation of activated leukocytes in the synovial membrane, causing pain, swelling and progres- sive joint destruction. The JAK-STAT signaling pathway is a conserved phosphorylation cascade with an important role in many inflammatory cellular processes. Disturbances in this pathway have been documented in autoimmune diseases such as RA. In this work we aimed to characterize peripheral blood leukocyte populations of untreated early arthritis patients (with <1 year of disease duration) and evaluate the effect of conventional treatment with methotrexate (MTX) on JAK-STAT signaling pathway. Moreover, a group of refractory RA patients was also recruited and the effect of upadacitinib, a JAK inhibitor recently approved for RA treatment, was assessed. We aimed to uncover new knowledge about the effect of upadacitinib on the immune system, particularly in the early phases of arthritis. We have found significant alterations in both the frequency and phenotype of immune cells' populations between controls and early arthritis patients, particularly in seropositive RA. Treatment with MTX restored some of these alterations, which supports its efficacy in disease amelioration. The measurement of STAT phosphorylation levels showed decreased STAT activation in early RA, which was maintained or exacerbated after conventional treatment with MTX, suggesting a role of JAK- STAT signaling pathway since early disease onset. In addition, we have found that upadacitinib main- ly affected the frequency of dendritic cell subpopulations and T cell phenotype, but did not signifi- cantly impact STAT phosphorylation levels in peripheral blood leukocytes from established refractory RA patients. Overall, our results support the immunomodulatory effects of MTX and upadacitinib in peripheral blood leukocytes from early and established arthritis patients and reinforce the role of JAK- STAT signaling pathway since early disease onset. |
id |
RCAP_549e25405154ffa39cf4ce4c1f7d40e1 |
---|---|
oai_identifier_str |
oai:run.unl.pt:10362/162939 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
The role of JAK-STAT signaling pathway in early arthritisRheumatoid arthritisJAK-STAT signaling pathwayleukocytesmethotrexateupadacitinibDomínio/Área Científica::Engenharia e Tecnologia::Outras Engenharias e TecnologiasRheumatoid arthritis (RA) is a systemic, inflammatory, immune-mediated disorder, impacting approximately 1% of the world population. It is characterized by chronic joint inflammation due to accumulation of activated leukocytes in the synovial membrane, causing pain, swelling and progres- sive joint destruction. The JAK-STAT signaling pathway is a conserved phosphorylation cascade with an important role in many inflammatory cellular processes. Disturbances in this pathway have been documented in autoimmune diseases such as RA. In this work we aimed to characterize peripheral blood leukocyte populations of untreated early arthritis patients (with <1 year of disease duration) and evaluate the effect of conventional treatment with methotrexate (MTX) on JAK-STAT signaling pathway. Moreover, a group of refractory RA patients was also recruited and the effect of upadacitinib, a JAK inhibitor recently approved for RA treatment, was assessed. We aimed to uncover new knowledge about the effect of upadacitinib on the immune system, particularly in the early phases of arthritis. We have found significant alterations in both the frequency and phenotype of immune cells' populations between controls and early arthritis patients, particularly in seropositive RA. Treatment with MTX restored some of these alterations, which supports its efficacy in disease amelioration. The measurement of STAT phosphorylation levels showed decreased STAT activation in early RA, which was maintained or exacerbated after conventional treatment with MTX, suggesting a role of JAK- STAT signaling pathway since early disease onset. In addition, we have found that upadacitinib main- ly affected the frequency of dendritic cell subpopulations and T cell phenotype, but did not signifi- cantly impact STAT phosphorylation levels in peripheral blood leukocytes from established refractory RA patients. Overall, our results support the immunomodulatory effects of MTX and upadacitinib in peripheral blood leukocytes from early and established arthritis patients and reinforce the role of JAK- STAT signaling pathway since early disease onset.A artrite reumatoide (AR) é uma doença sistémica, inflamatória, imunomediada, que afeta cerca de 1% da população mundial. É caracterizada por inflamação crónica das articulações, com acumulação de populações leucocitárias ativadas na membrana sinovial, causando dor, inchaço e des- truição da articulação. A via de sinalização JAK-STAT é uma cascata de fosforilação com um papel importante em vários processos inflamatórios. Alterações nesta via têm sido documentadas em doen- ças autoimunes, incluindo a AR. Este projeto teve como objetivo a caracterização das populações leucocitárias no sangue perifé- rico de doentes com artrite inicial não tratada, bem como a avaliação do efeito de tratamento conven- cional com metotrexato (MTX) na via JAK-STAT. Adicionalmente, um grupo de doentes com AR re- fratária foi recrutado de modo a analisar o efeito do upadacitinib, um inibidor da via JAK-STAT recen- temente aprovado no tratamento da AR. Pretendeu-se assim obter novo conhecimento sobre o efeito do upadacitinib no sistema imunitário, em particular na artrite inicial. Foram encontradas alterações significativas na frequência e fenótipo de populações leucocitá- rias entre controlos e doentes com artrite inicial, especialmente na AR seropositiva. O tratamento com MTX restaurou algumas dessas alterações, reforçando a sua eficácia clínica. A análise dos níveis de fosforilação das proteínas STAT revelou uma diminuição da sua ativação na AR inicial, resultado que se manteve ou foi acentuado com tratamento com MTX, sugerindo um papel da via JAK-STAT nas fases iniciais da doença. Observou-se que o upadacitinib influencia a frequência das subpopulações de células dendríticas e o fenótipo das células T, mas não afeta significativamente os níveis de fosforila- ção das STAT em doentes com AR refratária. De modo geral, estes resultados apoiam os efeitos imu- nomoduladores do MTX e do upadacitinib nos leucócitos em circulação de doentes com artrite inicial e refratária, e reforçam o papel da via JAK-STAT desde a fase inicial da doença.Moura, RitaRUNMariano, Ana Rita Faísca2024-01-31T10:44:57Z2023-122023-12-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/10362/162939enginfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:45:59Zoai:run.unl.pt:10362/162939Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:59:09.957487Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
The role of JAK-STAT signaling pathway in early arthritis |
title |
The role of JAK-STAT signaling pathway in early arthritis |
spellingShingle |
The role of JAK-STAT signaling pathway in early arthritis Mariano, Ana Rita Faísca Rheumatoid arthritis JAK-STAT signaling pathway leukocytes methotrexate upadacitinib Domínio/Área Científica::Engenharia e Tecnologia::Outras Engenharias e Tecnologias |
title_short |
The role of JAK-STAT signaling pathway in early arthritis |
title_full |
The role of JAK-STAT signaling pathway in early arthritis |
title_fullStr |
The role of JAK-STAT signaling pathway in early arthritis |
title_full_unstemmed |
The role of JAK-STAT signaling pathway in early arthritis |
title_sort |
The role of JAK-STAT signaling pathway in early arthritis |
author |
Mariano, Ana Rita Faísca |
author_facet |
Mariano, Ana Rita Faísca |
author_role |
author |
dc.contributor.none.fl_str_mv |
Moura, Rita RUN |
dc.contributor.author.fl_str_mv |
Mariano, Ana Rita Faísca |
dc.subject.por.fl_str_mv |
Rheumatoid arthritis JAK-STAT signaling pathway leukocytes methotrexate upadacitinib Domínio/Área Científica::Engenharia e Tecnologia::Outras Engenharias e Tecnologias |
topic |
Rheumatoid arthritis JAK-STAT signaling pathway leukocytes methotrexate upadacitinib Domínio/Área Científica::Engenharia e Tecnologia::Outras Engenharias e Tecnologias |
description |
Rheumatoid arthritis (RA) is a systemic, inflammatory, immune-mediated disorder, impacting approximately 1% of the world population. It is characterized by chronic joint inflammation due to accumulation of activated leukocytes in the synovial membrane, causing pain, swelling and progres- sive joint destruction. The JAK-STAT signaling pathway is a conserved phosphorylation cascade with an important role in many inflammatory cellular processes. Disturbances in this pathway have been documented in autoimmune diseases such as RA. In this work we aimed to characterize peripheral blood leukocyte populations of untreated early arthritis patients (with <1 year of disease duration) and evaluate the effect of conventional treatment with methotrexate (MTX) on JAK-STAT signaling pathway. Moreover, a group of refractory RA patients was also recruited and the effect of upadacitinib, a JAK inhibitor recently approved for RA treatment, was assessed. We aimed to uncover new knowledge about the effect of upadacitinib on the immune system, particularly in the early phases of arthritis. We have found significant alterations in both the frequency and phenotype of immune cells' populations between controls and early arthritis patients, particularly in seropositive RA. Treatment with MTX restored some of these alterations, which supports its efficacy in disease amelioration. The measurement of STAT phosphorylation levels showed decreased STAT activation in early RA, which was maintained or exacerbated after conventional treatment with MTX, suggesting a role of JAK- STAT signaling pathway since early disease onset. In addition, we have found that upadacitinib main- ly affected the frequency of dendritic cell subpopulations and T cell phenotype, but did not signifi- cantly impact STAT phosphorylation levels in peripheral blood leukocytes from established refractory RA patients. Overall, our results support the immunomodulatory effects of MTX and upadacitinib in peripheral blood leukocytes from early and established arthritis patients and reinforce the role of JAK- STAT signaling pathway since early disease onset. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-12 2023-12-01T00:00:00Z 2024-01-31T10:44:57Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/162939 |
url |
http://hdl.handle.net/10362/162939 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799138171707981824 |